Aptose Biosciences Inc. (APTO) Price Target Cut to $12.00
Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) had its price objective reduced by investment analysts at RBC Capital Markets from $18.00 to $12.00 in a research note issued to investors on Wednesday. The brokerage currently has an “outperform” rating on the stock.
Other research analysts have also recently issued research reports about the stock. Roth Capital reiterated a “buy” rating and set a $8.00 price target on shares of Aptose Biosciences in a report on Friday, October 14th. Canaccord Genuity reiterated a “buy” rating and set a $7.00 price target on shares of Aptose Biosciences in a report on Saturday, October 15th. Zacks Investment Research upgraded shares of Aptose Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 11th. Finally, Royal Bank Of Canada lowered their price target on shares of Aptose Biosciences from $18.00 to $12.00 and set an “outperform” rating for the company in a report on Wednesday. Six investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average price target of $9.50.
Aptose Biosciences (NASDAQ:APTO) opened at 0.92 on Wednesday. The stock’s market cap is $11.86 million. Aptose Biosciences has a one year low of $0.83 and a one year high of $4.33. The company’s 50 day moving average is $1.65 and its 200 day moving average is $2.24.
A hedge fund recently bought a new stake in Aptose Biosciences stock. Bank of Montreal Can bought a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned 0.43% of Aptose Biosciences as of its most recent filing with the SEC. Institutional investors own 19.19% of the company’s stock.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Stock Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related stocks with our FREE daily email newsletter.